Main Article Content
Aims: To compare the effectiveness of treatment with METFORMIN alone and with a combination of METFORMIN and SIMVASTATIN in the management of polycystic ovarian syndrome.
Study Design: Randomized Clinical Trial.
Place and Duration of Study: Department of Obstetrics and Gynecology (Infertility Unit) at District Headquarter (DHQ) Teaching Hospital, Sahiwal (Pakistan) during June to September, 2018.
Methodology: 162 patients were randomly divided into METFORMIN group (n=81) and METFORMIN plus SIMVASTATIN group (n=81), detailed clinical history, including menstrual details, was taken with thorough examination performed. Baseline ultrasound was performed to evaluate the ovarian size and these were considered enlarged with volume >10cc or with >12 follicles in any one ovary. Blood samples were taken at baseline and after three months of therapy to determine the LH/FSH ratio and lipid profile. Efficacy was defined as >15% decrease in the baseline values.
Results: The mean age of the patients was 27.12 ±8.17 years, and the mean BMI was 24.21 ±2.2 Kg/m2. Efficacy was achieved in 67.1% patients with METFORMIN alone, while in 92.6% with combination medication (p=0.0068).
Conclusion: Managing the women having PCOS with the combination of METFORMIN and SIMVASTATIN is more beneficial as compared to treatment with METFORMIN alone.